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Abstract Primary systemic amyloidosis (AL amyloidosis)
continues to have a very poor prognosis. Most therapeutic
strategies remain unsatisfactory. Conventional chemotherapy
is known to offer at best only moderate efficacy. Several
studies have yielded higher complete response rates after
high-dose chemotherapy and autologous stem cell transplan-
tation (ASCT) in addition to improving outcomes in a
subgroup of patients. However, the superiority of an intensive
approach in AL amyloidosis has not been confirmed in a
randomised trial. The precise role of ASCT remains unclear.
We report our experience in 16 patients diagnosed with AL
amyloidosis and treated in a multidisciplinary approach with
high-dose melphalan and ASCT. Median age was 59 (39–
71) years. The kidneys were predominantly affected in 75% of
cases; two or more organs were affected in 38%. Median time
from diagnosis to transplantation was 2 (1–4) months. Three
patients (19%) developed acute renal failure and required
transient dialysis. Transplant-related mortality was 6% after
100 days. Haematological complete response (CR) was
obtained in nine (56%) and organ response in six (38%)
patients. Nine out of 12 patients (75%) with kidney
involvement exhibited a sustained clinical benefit at
12 months. Half of all the patients (n=8) were alive after a
median follow-up of 33 months, including two in continuous
CR. This suggests that high-dose chemotherapy and ASCT
are still valid treatment options in AL amyloidosis and that a
significant number of patients with renal involvement might
benefit from this approach.
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Introduction
Primary systemic amyloidosis (AL amyloidosis) is a rare
clonal plasma cell disorder whose prognosis has been dismal
due to widespread organ involvement and a limited range of
available therapeutic options. Conventional chemotherapy
with oral melphalan combined with prednisone has long
been the standard treatment, with less than 25% response
rates and a rather modest effect on survival [1]. Several
studies have recently shown that high-dose melphalan
followed by autologous stem cell transplantation (ASCT)
could yield a high rate of complete responders [2, 3] in
addition to improving long-term outcomes among selected
patients [4–6]. The same intensive approach was also shown
to improve substantially both the performance status and the
quality of life of good responders [7, 8].
However, the benefit of ASCT in the treatment of AL
amyloidosis remains debatable. A multicentric randomised
trial failed to confirm the superiority of an intensive to a
standard approach [9]. An important limiting factor is
transplant-related mortality (TRM), as the rate of around
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13% obtained in expert centres might be considerably
higher in less-experienced hands [4, 5]. Recent findings
have shown a large potential improvement of patients’
outcome by optimising clinical management in the peri-
operative course of ASCT and by adopting a risk-adapted
approach [2, 10]. The present study illustrates our longitu-
dinal experience with early intensification in AL amyloid-
osis based on 16 patients treated at a single centre.
Study design
A total of 16 patients with advanced systemic AL amyloid-
osis were selected for treatment with high-dose melphalan
followed by ASCT at our centre between 1997 and 2005. All
patients had biopsy-proven amyloidosis and evidence of
plasma cell dyscrasia. Visceral involvement was diagnosed
as outlined by the International Consensus Opinion [11]. All
patients were enrolled in our institutional ASCT programme
and gave their written informed consent in accordance with
the Declaration of Helsinki. The analysis of this series was
performed according to quality assessment by general
authorisation of the local Ethics Committee.
The decision to perform intensive therapy was reached
on the basis of specific multidisciplinary assessments
including specialised renal and cardiac examinations.
Neurological evaluation was performed when appropriate.
Peripheral stem cells were mobilised using either granulo-
cyte-colony-stimulating factor (G-CSF) or cyclophospha-
mide+G-CSF. Subsequently a conditioning regimen of
melphalan 140 or 200 mg/m2 was administered. Patients
with both renal and extra-renal disease were treated in the
intensive care unit. All patients received multidisciplinary
care throughout the hospitalisation period, including daily
evaluations by a nephrologist.
Response was analysed 100 days after transplantation
according to the International Consensus Opinion [11]. Free
light chains measurement not being available in all cases,
patients with negative immunofixation in serum and urine and
with <5% plasma cells in BM were considered in haemato-
logical CR. TRM was assessed 3 months after transplant.
Results
Patient data are listed in Table 1 and their clinical
parameters in Table 2. Median age was 59 (39–71) years.
Kidneys were involved as the predominant organ in 12 out
of 16 cases (75%). Two or more organs were infiltrated in
six cases (38%). Median time from diagnosis to transplan-
tation was 2 (1–4) months. A median of 5.05×106 CD34+
cells/kg (range, 2.5–11.7×106) was administered. Patients
were hospitalised for a median of 26 (13–67) days.
Most treatments were performed in the intensive care
unit, but patients with purely renal involvement (n=7) were
treated in the transplantation unit with close renal monitor-
ing. Of the 12 patients with predominantly renal involve-
ment, three developed acute renal failure requiring initiation
of dialysis. Renal function swiftly recovered in two of them
during hospitalisation; in the third case, dialysis could be
discontinued 3 months after transplantation.
One 70-year-old patient (#7) died from sepsis and multi-
organ failure on day 11 after transplantation. No other
deaths occurred within 100 days of treatment. Thus the rate
of TRM was 6%. Nine patients (56%) showed haemato-
logical CR and remained complete responders for a median
of 31 (8–97) months. Organ response was obtained in six
patients (38%; Table 2).
Of the 12 patients with kidney involvement, a total of four
(33%) met the criteria for renal response at 12 months and
five (42%) exhibited prolonged stabilisation of renal func-
tion. Thus the overall rate of sustained clinical benefit was
75%. Fourteen of the 16 patients survived longer than 1 year.
A total of eight patients died after a median follow-up period
of 33 months, including one who was progression-free and
who died 55 months following transplantation. Eight patients
(50%) survived (Fig. 1). Two survivors continuously showed
CR after 82 and 97 months respectively.
Table 1 Patient characteristics at baseline
Patient characteristics
No. of patients 16
Median age (years) 59 (39–71)
Male/female 8/8
ECOG performance status (median) 2 (1–3)
Monoclonal gammapathy (No.)
Lambda 15
Kappa 1
Proteinuria (median g/l)a 6 (0.08–26.8)
Serum albumin (median g/dl) 26 (15–43)
Serum creatinine (median μmol/l)b 78 (38–208)
Creatinine clearance evaluation (median ml/min) 72 (35–154)
Serum alkaline phosphatase (median U/l) 103 (53–712)
Major organs involved (median no.)c 1 (1–3)
No. of patients with ≥2 organs involved 6
Left ventricular ejection fraction (median %) 60 (30–88)
Time from diagnosis to transplantation
(median months)
2 (1–4)
Mobilisation (No.)
G-CSF 15
Cyclophosphamide+G-CSF 1
Conditioning regimen (No.)
Melphalan 140 mg/m2 4
Melphalan 200 mg/m2 12
a Data on 15 patients only
b Cockcroft-Gault
c Including kidney, heart, nerves or liver only
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Discussion
The present series has yielded encouraging results in 16
patients with AL amyloidosis treated by high-dose melpha-
lan chemotherapy and ASCT. A 6% rate of TRM observed
on day 100 after transplantation compares favourably with
the findings of other trials [4, 5, 12]. A meta-analysis of
single-centre trials (covering 10 to 30 intensified patients
each) yielded an average TRM of 21% [2] and a 13% rate
of TRM has been reported in expert centres [4, 5]. More
recently, Cohen et al. described a TRM of 4.4% using a
risk-adapted approach [10].
We do not believe that our results have been influenced
by selecting patients with a good prognosis. Their median
age was 59 years while most other series included patients
aged between 48 and 55 [8, 13]. One-third of our patients
were over 65. While a risk-adapted approach is generally
taken today and is well-acknowledged to offer better results,
our series covers a time span large enough for this approach
not to have been generally used [2, 14]. Most of our patients
were treated with melphalan 200 mg/m2 as the conditioning
regimen despite their generally advanced age and despite
involvement of two or more organs in several cases.
Overall toxicity was manageable. Transient acute renal
failure occurred in 25% of cases, which is consistent with
previous reports [15]. Haematological complete response
and organ response were observed in 56% and 38% of
patients respectively. The identification of a correlation
between organ response and haematological complete
response is consistent with previous studies [16]. It is
interesting to note that 75% of patients showed stabilisation
of renal function and clinical improvement without meeting
the criteria of organ response.
Several factors may explain the encouraging findings
obtained in this small retrospective series. Single-centre trials
have been known to involve lower rates of TRM than
Table 2 Clinical manifestations (at the time of autologous stem cell transplantation) and outcomes
Patient Age Predominant
organ
involved
Other
organs
involved
Time from
diagnosis to
transplantation
Haematological
response at
3 months
Duration of
haematological
complete
response
Organ
response at
12 months
Survival
(months)
Cause
of death
1 61 Kidney ST 2 m CR 55 + Died at +55 Sepsis,
arrhythmia
2 39 Heart G, ST, LN 3 m CR 55 + Died at +57 Progression
3 60 Kidney H, ST 1 m CR 97 + Alive at +97
4 71 Heart 2 m CR 13 + Died at +58 Sudden
death
5 67 Liver K, LN 2 m ND NA Died at +5 Progression
6 56 Neuropathy G, ST 2 m CR 82 SD Alive at +82
7 70 Kidney 2 m NA NA Died at +0.5 TRM
8 41 Kidney N 1 m CR 8a SD Alive at +55
9 62 Kidney H, N, ST 3 m CR 23 SD Died at +31 Progression
10 58 Kidney 3 m PR + Alive at +34
11 50 Kidney H 3 m CR 10a SD Alive at +49
12 55 Kidney 2 m SD SD Alive at +25
13 67 Kidney 4 m PD PD Died at +18 Progression
14 57 Kidney N 2 m ND SD Alive at +25
15 66 Kidney 3 m CR 31 + Died at +53 Progression
16 39 Kidney 4 m SD PD Alive at +15
Abbreviations: CR complete response, G gut, H heart, K kidney, L liver, LN lymph nodes, N neuropathy, ND not done, PD progressive disease,
PSCT peripheral stem cell transplantation, SD stable disease, ST soft tissue, TRM treatment-related mortality
a Second ongoing CR following high-dose dexamethasone
Fig. 1 Overall survival time after months post ASCT
Ann Hematol (2009) 88:681–685 683
multicentric trials [2, 10]. The time from diagnosis to
transplantation (median of 2 months) was well below the
range of 4 to 16 months documented in other studies [8, 13].
The median time from harvesting peripheral stem cells to
transplantation was only 11 days. This would support the
notion that the delay due to induction treatment before high-
dose therapy might compromise survival in high-risk
patients, particularly in the case of cardiac involvement [17].
The question of optimal timing for high-dose melphalan
in AL amyloidosis remains debatable following reports on a
negative impact of early intensification [12]. This effect may
have been due to selection of high-risk patients requiring
urgent treatment. We hypothesize that most of our patients
would not have benefited from frontline chemotherapy,
given their advanced age, and that early intensification may
have contributed to their favourable outcomes. Moreover,
multidisciplinary management was initiated at an early stage
and most of the patients were intensified in the intensive care
unit. Owing to this specialised management, four patients
had a favourable outcome after transplantation despite
experiencing grade 3/4 non-haematological toxicities involv-
ing ≥3 systems. Other authors have emphasised the
importance of careful peri-transplantation evaluation and
the need for highly specialised management provided by a
well-trained team [2].
Our findings indicate that early treatment with high-dose
melphalan may reverse the course of AL amyloidosis and
might improve outcomes in a subset of patients, although a
randomised trial has failed to confirm superiority of ASCT
[9]. Benefits might be confined to a minority of patients
treated in tertiary referral centres. We expect that new
biomarkers predictive of toxicity and response will be
introduced to facilitate patient selection for ASCT [13, 18,
19]. Moreover, the combination of biological agents with
ASCT might improve results following an intensive
approach [10]. Also, there is a pressing need for other
effective treatment modalities in patients too sick for
intensive therapy. Preliminary studies on bortezomib or
immunomodulatory agents have yielded promising results
[20]. Thalidomide combined with dexamethasone or che-
motherapy has demonstrated significant efficacy [21].
Preliminary results demonstrating that lenalidomide also
has good efficacy and a vastly better toxicity profile are
promising and warrant further studies [22, 23]. The
available evidence calls for larger studies to define more
accurately the role of ASCT in AL amyloidosis.
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